Eosinophilic inflammation: a key player in COPD pathogenesis and progression

Lee, Yueh Luen and Heriyanto, Didik Setyo and Yuliani, Fara Silvia and Laiman, Vincent and Choridah, Lina and Lee, Kang Yun and Chang, Jer Hwa and Chung, Kian Fan and Chang, L. T. and Chang, Tayuan and Chuang, Hsiao-Chi (2024) Eosinophilic inflammation: a key player in COPD pathogenesis and progression. Annals of Medicine, 56 (1): 2408466. pp. 1-15. ISSN 13652060; 07853890

[thumbnail of 354_Yueh-Lun Lee.pdf] Text
354_Yueh-Lun Lee.pdf - Published Version
Restricted to Registered users only
Available under License Creative Commons Attribution.

Download (1MB) | Request a copy

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) remains a significant public health challenge due to its high morbidity and mortality rates. Emerging research has identified eosinophilic inflammation as a crucial factor in the pathogenesis and exacerbation of COPD, warranting a detailed exploration of its underlying mechanisms and therapeutic implications. Objective: This review aims to elucidate the role of eosinophils in COPD, focusing on their contribution to airway remodeling, exacerbation frequency, and the inflammatory cascade. Methods: We conducted a comprehensive literature review of recent studies that discuss the pathophysiological role of eosinophils in COPD and the clinical outcomes associated with modulating eosinophilic activity. Results: Eosinophils contribute to COPD progression by releasing cytotoxic proteins and cytokines that intensify the inflammatory response and airway alterations. Targeting specific eosinophil-related cytokines with monoclonal antibodies or receptor antagonists may potentially reduce eosinophil counts, mitigate exacerbations, and improve patient outcomes. Conclusion: Understanding eosinophilic involvement in COPD can facilitate the development of precision medicine approaches, offering more tailored and effective treatment options. Future research should continue to focus on the integration of eosinophil biomarkers in clinical practice to enhance therapeutic decisions and management strategies for COPD patients. © 2024 Elsevier B.V., All rights reserved.

Item Type: Article
Additional Information: Cited by: 5; All Open Access; Gold Open Access; Green Final Open Access; Green Open Access
Uncontrolled Keywords: cytotoxic factor; interleukin 4; monoclonal antibody; biological marker; cytokine; airway remodeling; allergy; chronic obstructive lung disease; clinical outcome; clinical practice; defense mechanism; disease exacerbation; eosinophil; eosinophil count; eosinophilia; human; leukocyte; Medline; obstructive lung disease; pathogenesis; Review; search engine; Web of Science; immunology; inflammation; metabolism; pathophysiology; Airway Remodeling; Biomarkers; Cytokines; Disease Progression; Eosinophilia; Eosinophils; Humans; Inflammation; Pulmonary Disease, Chronic Obstructive
Subjects: R Medicine > RB Pathology
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Medicine, Public Health and Nursing > Biomedical Sciences
Depositing User: Ngesti Gandini
Date Deposited: 08 Oct 2025 06:21
Last Modified: 08 Oct 2025 06:21
URI: https://ir.lib.ugm.ac.id/id/eprint/22380

Actions (login required)

View Item
View Item